

**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

August 13, 2018

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Annual General Meeting and Book Closure Notice**

**Ref: Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that the Annual General Meeting of the Company is scheduled to be held on **Thursday, September 6, 2018 at 3:00 p.m. at Rama Watumull Auditorium, Kishinchand Chellaram College, 124, Dinshaw Wachha Road, Churchgate, Mumbai 400020.** We hereby enclose a copy of the Annual Report of the Company for the Financial Year ended March 31, 2018 for your reference.

This is to further inform you that the Register of Members and the Share Transfer Books of the Company will remain closed from **Friday, August 31, 2018 to Thursday, September 6, 2018 (both days inclusive).**

Security Code	Type of Security	Book Closure		Purpose
		From	To	
500680 (BSE) PFIZER EQ (NSE)	Equity Share	August 31, 2018 (Friday)	September 6, 2018 (Thursday)	Payment of Dividend

As informed earlier, the Board at the Meeting held on May 7, 2018 had recommended dividend of Rs. 20.00/- (200%) per equity share for the financial year ended March 31, 2018. The same if approved by the members at the ensuing Annual General Meeting would be paid on September 11, 2018.




Further please note that the cut-off date for determining the eligibility of members to vote through remote e-voting or poll is Thursday, August 30, 2018.

Request you to take the above on record.

Thanking you,

Yours truly,  
For Pfizer Limited

A handwritten signature in black ink, appearing to read 'Prajeet Nair', with a long horizontal stroke extending to the right.

**Prajeet Nair**  
**Company Secretary**

**Cc:     National Securities Depository Limited (NSDL)**  
**Central Depository Services (India) Limited (CDSL)**  
**Karvy Computershare Private Limited (Registrar & Share Transfer Agent)**



Pfizer Limited

# Lead

A legacy of leadership in  
anti-infectives / Page 18

---

# Educate

Initiatives to combat antimicrobial  
resistance / Page 22

---

# Advocate

Rational use of antibiotics /  
Page 28

---

# Develop

Pipeline to tackle infectious  
diseases / Page 32


---

**ANNUAL REPORT  
2017-18**



# Lead. Educate. Advocate. Develop.

**Our Annual Report this year, with the theme Lead, Educate, Advocate, Develop (LEAD), puts the spotlight on Pfizer's journey to become the world's leading anti-infectives company and our continuing efforts to help combat antimicrobial resistance.**



## Index

### Corporate Overview

Antimicrobial Resistance (AMR) – An introduction	2
Pfizer at a glance	4
Key products	6
Key performance highlights	8
Message from the Managing Director	10
AMR – A new age health crisis	12
Lead: A legacy of leadership	18

Educate: Through initiatives to combat AMR	22
Advocate: Rational use of antibiotics	28
Develop: Pipeline to tackle infectious diseases	32
Corporate social responsibility	34
Board of Directors	44
Leadership team	46
Corporate information	48

### Statutory Reports

Notice	49
Board's Report including Management Discussion and Analysis Report	58
Corporate Governance Report	98
Business Responsibility Report	112

### Financial Statements

Independent Auditor's Report	119
Balance Sheet	126
Statement of Profit and Loss	127
Statement of Cash Flows	128
Statement of Changes in Equity	130
Notes to the Financial Statements	131



*"The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism."*

**Sir Alexander Fleming**  
Discovered Penicillin in 1928



*"India recognizes Antimicrobial Resistance (AMR) as one of the major global threats to public health and we are committed to prevent, contain and combat this major health threat. The National Centre of Disease Control and the Indian Council of Medical Research are engaged in AMR surveillance. However, its prevention and containment requires multi-sectoral and multi-stakeholder action. India is committed to fully support global efforts to prevent and contain antimicrobial resistance."*

**Shri Narendra Modi**  
Prime Minister of India

[Source: PM Modi takes pledge to support AMR; Economic Times (online article), May 24, 2016]



*"Some experts say we are moving back to the pre-antibiotic era. This will be a post-antibiotic era... in effect, an end to modern medicine as we know it. Things as common as strep throat or a child's scratched knee could once again kill."*

**Ms. Margaret Chan**  
Former Director General, World Health Organization

[Source: Keynote address at Combating Antimicrobial Resistance: time for action in Copenhagen, March 14, 2012]



*"Antimicrobial resistance is a serious threat to global public health that requires action across all government sectors and society and is driven by many interconnected factors. Single, isolated interventions have limited impact and coordinated action is required to minimize the emergence and spread of antimicrobial resistance."*

**Shri J P Nadda**  
Union Minister of Health and Family Welfare, Government of India

[Source: Stated at the 'Inter-Ministerial Consultation on AMR containment', April 19, 2017]



Lead. Educate. Advocate. Develop.

Deaths caused globally by AMR

**7,50,000\***  
annually



People developed multi-drug resistant  
TB globally

**4,90,000**  
in 2016



Deaths expected to be caused by AMR

**10 million\***  
by 2050



\*Source: The Review on Antimicrobial  
Resistance Chaired by Jim O'Neill,  
December 2014

## ANTIMICROBIAL RESISTANCE (AMR) – AN INTRODUCTION

### What is AMR?

The World Health Organization describes Antimicrobial Resistance (AMR) as the ability of a microorganism (like bacteria, virus and some parasites) to stop an antimicrobial (such as an antibiotic, an antiviral and an antimalarial) from working against it – rendering standard treatments ineffective and causing infections to persist and spread. Across the world, experts are calling out AMR as the single most significant medical challenge of our times, a phenomenon that threatens to rapidly deplete the world's resources to fight pathogens.

Countering this medical crisis requires interventions and leadership on several fronts, which includes:

- Enhancing our understanding of resistance patterns through better surveillance and mounting global interventions towards rational prescription; dispensation and use of antibiotics are key interventions required
- Strengthening the global portfolio of available antimicrobials, making massive efforts towards disease prevention, control and immunization have been acknowledged as being instrumental in achieving this





## PFIZER IS COMMITTED TO MAKING A DIFFERENCE

From the time that we pioneered the mass production of **Penicillin**, credited with saving countless lives in World War II, Pfizer has remained the leading anti-infectives company of the world. Over the decades since, the Company has discovered and brought to market some of the world's most important antimicrobials and iconic anti-infective brands.

**Terramycin®**, a broad-spectrum antibiotic – an outcome of Pfizer's first discovery program; **Diflucan®** – Pfizer's discovery that has remained the mainstay to counter fungal infections and **Zithromax** emerged as a standard of care in respiratory infections; each of these have been Pfizer's landmark contribution to the world's anti-infective arsenal.

Today, Pfizer continues to **LEAD** the industry with the widest portfolio of anti-infectives and strategic investments in the development of new therapies for the future.

Our leadership position in this therapeutic area also brings with it a responsibility to partner stakeholders across the world in combating AMR through concentrated efforts in the areas of surveillance and stewardship.

Through the **Pfizer ATLAS program – one of the largest surveillance programs in the world** – we gather and disseminate information on resistance patterns across the world. We continue to partner with research organizations, infectious disease specialists' communities and institutions to advance stewardship efforts aimed at rational use of antimicrobials. Through these and other initiatives, we aim to **EDUCATE** stakeholders with information and best practices to help keep today's antimicrobials effective for longer.

As an original signatory to the **Davos Declaration on Antimicrobial Resistance** 2016, Pfizer plays a key role to **ADVOCATE** and help shape policies that combat AMR. Pfizer Inc's collaboration with the government of China through Project Navigator has not only created a robust surveillance network to track resistance patterns, but has also helped shape policies around rational use of antibiotics.

In India, we were one of the select companies called upon to provide recommendations on operationalizing the National Action Plan on AMR by the WHO and the Government of India. **Our partnership with Indian Council of Medical Research (ICMR) – to set up a Centre to Combat AMR – is the first of its kind in the country.** Through this dedicated Centre at New Delhi, this initiative will design and implement a series of interventions in the areas of Surveillance, Stewardship and Advocacy and Awareness nationwide.

As we strengthen these efforts to preserve the efficacy of today's drugs for longer, Pfizer continues to **DEVELOP** new therapies to provide solutions for tomorrow. Pfizer's commitment to R&D supports development of medicines for both, the treatment and prevention of infections caused by resistant pathogens.

Read about the above stories and more in our Annual report this year, themed – **LEAD**. It will give you an insight into Pfizer's leadership in anti-infectives and collaborations with partners to take on the global threat of AMR.





# Pfizer at a glance

## Our purpose

Innovate to bring therapies to patients that significantly improve their lives.

*With more than 140 R&D collaborations, 63 manufacturing sites and over 91,000 colleagues across the world, Pfizer is committed to working with patients, healthcare providers and governments to help protect and enhance public health.*



### PFIZER INC.

Pfizer Inc., the parent Company of Pfizer Limited, was founded in New York in 1849. Today, it is the world's premiere biopharmaceutical corporation with annual revenues of \$52.5 billion in 2017. It produces and markets its medicines, vaccines and other consumer healthcare products across 175 markets globally.

Pfizer offers the industry's largest and one of the most diverse portfolios of anti-infectives, that includes more than 80 medicines. We are proud of our longstanding heritage of partnering the infectious diseases community to address evolving and unmet medical needs.

The Company's rich and diverse pipeline includes small-molecule drugs, large-molecule biotherapeutics such as antibodies, cell and gene-based therapies and vaccines. For each of these programs, Pfizer scientists draw on a wealth of state-of-the-art science and technology spanning many disciplines, with a single aim to deliver best-in-class treatment to patients. We work to translate advanced science and technologies into the therapies that matter most.

Pfizer Inc. manages its commercial operations through two businesses: Pfizer Innovative Health and Pfizer Essential Health.

### PFIZER INNOVATIVE HEALTH (PIH)

The Innovative Health portfolio is focused on improving health with innovative medicines and vaccines – from prevention to treatment and wellness at every stage of life.

The PIH commitment of 'patients first' guides every action, informs every strategic decision and unifies colleagues in every region and function across our therapeutic categories – Inflammation & Immunology, Internal Medicine (cardiovascular and metabolic diseases and pain), Oncology, Rare Disease and Vaccines.

The PIH Patient and Health Impact group develops solutions for increased patient access, demonstrates the value of its innovations and ensures broader business model innovation.

With a renewed mission and bold structure designed to amplify each group's strengths, PIH is positioned to lead change for healthcare around the world.

### PFIZER ESSENTIAL HEALTH (PEH)

The Essential Health business brings a portfolio of well-known branded medicines including many of Pfizer's most iconic brands to serve as a critical partner in the global public health community. Our essential health business is a leader in non-viral anti-infectives, biosimilars and sterile injectable medicines.

At PEH, we combine our history of industry, leadership, comprehensive knowledge of global healthcare markets, and a vast portfolio of trusted, quality medicines to benefit patients around the world at virtually every stage of life.

PEH strives to transform insights into action through its global reach, the breadth of knowledge and the depth of its capabilities, delivering value to health systems in over 160 countries.

Whether it's using new technology and our deep experience to increase access to an essential medicine or combat an emerging health risk, or ability to innovate and anticipate customer and patient needs, our work continues to allow us to make meaningful and inspired contributions for improving health.

Non-viral anti-infective company

**#1**  
globally







Images are for  
representational  
purpose only.

## PFIZER LIMITED

Pfizer Limited began its operations in India in 1950. Today, with an annual sales of ₹ 1,925 crores, it is the third-largest pharmaceutical multinational company in the country. It has a portfolio of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13, Lyrica, Eliquis, Enbrel, Becosules, Gelusil and Corex range of products.

The Company enjoys a unique advantage of access to Pfizer Inc's global portfolio of therapies for introduction in the Indian market. Its portfolio in India consists of around 50% global brands such as Prevenar13, Lyrica, Eliquis, Xeljanz, around 25% brands with global lineage like Dolonex and Amlogard, and 25% local brands. The homegrown brands, such as Gelusil, Becosules, Folvite and Corex range, continue to be an essential and widely recognized part of the Company's portfolio and revenues in India. These have been strengthened with line extensions.

Going forward, the success of global brands, such as Meronem, Nexsium and Xeljanz launched in the last two years will play a key role in fueling the growth of the Company.

Pfizer Limited has the distinction of being the first pharmaceutical company in India to start clinical research. The Company has a state-of-the-art and award winning manufacturing facility in Goa that produces more than a billion tablets annually.

Employing 2,630 colleagues across commercial operations, manufacturing and other functions, Pfizer Limited is committed to providing therapies to prevent, treat and cure some of the most critical diseases that impact public health in India today.

## Leadership in India

Non-viral anti-infective injectable space

**#1 MNC**



17 brands are

**#1**  
in their representative  
product market



Prevenar 13 value market share of

**58.17%**



\*Source: IQVIA MAT March 2018

# Key products

## INNOVATIVE GLOBAL BRANDS

Prevenar 13



Lyrica, Ativan



Viagra



Zosyn



Minipress XL



Meropenem



Enbrel



## BRANDS WITH GLOBAL LINEAGE

Dolonex



Magnex



Amlogard



Trulimax



Daxid



Neksium

